270 related articles for article (PubMed ID: 18376126)
1. The effect of atorvastatin treatment on lipid profile and adhesion molecule levels in hypercholesterolemic patients: relation to low-density lipoprotein receptor gene polymorphism.
Bolewski A; Lipiecki J; Plewa R; Burchardt P; Siminiak T
Cardiology; 2008; 111(2):140-6. PubMed ID: 18376126
[TBL] [Abstract][Full Text] [Related]
2. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
3. Reduction in serum levels of adhesion molecules, interleukin-6 and C-reactive protein following short-term low-dose atorvastatin treatment in patients with non-familial hypercholesterolemia.
Nawawi H; Osman NS; Yusoff K; Khalid BA
Horm Metab Res; 2003 Aug; 35(8):479-85. PubMed ID: 12953165
[TBL] [Abstract][Full Text] [Related]
4. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets?
Piorkowski M; Fischer S; Stellbaum C; Jaster M; Martus P; Morguet AJ; Schultheiss HP; Rauch U
J Am Coll Cardiol; 2007 Mar; 49(10):1035-42. PubMed ID: 17349882
[TBL] [Abstract][Full Text] [Related]
5. Effect of atorvastatin on the expression of CD40 ligand and P-selectin on platelets in patients with hypercholesterolemia.
Hwang YS; Tsai WC; Lu YH; Lin CC; Chen YF
Am J Cardiol; 2004 Aug; 94(3):364-6. PubMed ID: 15276107
[TBL] [Abstract][Full Text] [Related]
6. Effects of toll-like receptor-4 gene polymorphisms on soluble P-selectin and von Willebrand factor levels in hypercholesterolemic patients.
Di Nisio M; Di Febbo C; Moretta V; Guglielmi MD; Stuppia L; Cuccurullo F; Porreca E
Thromb Haemost; 2007 Sep; 98(3):642-6. PubMed ID: 17849054
[TBL] [Abstract][Full Text] [Related]
7. Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration.
Blanco-Colio LM; Martín-Ventura JL; de Teresa E; Farsang C; Gaw A; Gensini G; Leiter LA; Langer A; Martineau P; Egido J;
Am Heart J; 2007 May; 153(5):881-8. PubMed ID: 17452168
[TBL] [Abstract][Full Text] [Related]
8. Effects of atorvastatin on Lp(a) and lipoprotein profiles in hemodialysis patients.
Joy MS; Dornbrook-Lavender KA; Chin H; Hogan SL; Denu-Ciocca C
Ann Pharmacother; 2008 Jan; 42(1):9-15. PubMed ID: 18000162
[TBL] [Abstract][Full Text] [Related]
9. Levels of adhesion molecules do not decrease after 3 months of statin therapy in moderate hypercholesterolaemia.
Jilma B; Joukhadar C; Derhaschnig U; Rassoul F; Richter V; Wolzt M; Dorner GT; Petternel V; Wagner OF
Clin Sci (Lond); 2003 Feb; 104(2):189-93. PubMed ID: 12546641
[TBL] [Abstract][Full Text] [Related]
10. Atorvastatin has hypolipidemic and anti-inflammatory effects in apoE/LDL receptor-double-knockout mice.
Nachtigal P; Pospisilova N; Jamborova G; Pospechova K; Solichova D; Andrys C; Zdansky P; Micuda S; Semecky V
Life Sci; 2008 Mar; 82(13-14):708-17. PubMed ID: 18289605
[TBL] [Abstract][Full Text] [Related]
11. Effect of lipid-lowering therapy with atorvastatin on atherosclerotic aortic plaques detected by noninvasive magnetic resonance imaging.
Yonemura A; Momiyama Y; Fayad ZA; Ayaori M; Ohmori R; Higashi K; Kihara T; Sawada S; Iwamoto N; Ogura M; Taniguchi H; Kusuhara M; Nagata M; Nakamura H; Tamai S; Ohsuzu F
J Am Coll Cardiol; 2005 Mar; 45(5):733-42. PubMed ID: 15734619
[TBL] [Abstract][Full Text] [Related]
12. Atorvastatin increases expression of low-density lipoprotein receptor mRNA in human circulating mononuclear cells.
Pocathikorn A; Taylor RR; Mamotte CD
Clin Exp Pharmacol Physiol; 2010 Apr; 37(4):471-6. PubMed ID: 19930424
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease.
Leiter LA; Bays H; Conard S; Bird S; Rubino J; Hanson ME; Tomassini JE; Tershakovec AM
Am J Cardiol; 2008 Dec; 102(11):1495-501. PubMed ID: 19026303
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
[TBL] [Abstract][Full Text] [Related]
15. The comparison of the effects of standard 20 mg atorvastatin daily and 20 mg atorvastatin every other day on serum LDL-cholesterol and high sensitive C-reactive protein levels.
Keleş T; Akar Bayram N; Kayhan T; Canbay A; Sahin D; Durmaz T; Ozdemir O; Aydoğdu S; Diker E
Anadolu Kardiyol Derg; 2008 Dec; 8(6):407-12. PubMed ID: 19103535
[TBL] [Abstract][Full Text] [Related]
16. Baseline levels of low-density lipoprotein cholesterol and lipoprotein (a) and the AvaII polymorphism of the low-density lipoprotein receptor gene influence the response of low-density lipoprotein cholesterol to pravastatin treatment.
Lahoz C; Peña R; Mostaza JM; Laguna F; García-Iglesias MF; Taboada M; Pintó X
Metabolism; 2005 Jun; 54(6):741-7. PubMed ID: 15931608
[TBL] [Abstract][Full Text] [Related]
17. Antioxidant effect of atorvastatin is independent of PON1 gene T(-107)C, Q192R and L55M polymorphisms in hypercholesterolaemic patients.
Sardo MA; Campo S; Bonaiuto M; Bonaiuto A; Saitta C; Trimarchi G; Castaldo M; Bitto A; Cinquegrani M; Saitta A
Curr Med Res Opin; 2005 May; 21(5):777-84. PubMed ID: 15969877
[TBL] [Abstract][Full Text] [Related]
18. Lectin-like oxidized-LDL receptor-1 (LOX-1) polymorphisms influence cardiovascular events rate during statin treatment.
Puccetti L; Pasqui AL; Bruni F; Pastorelli M; Ciani F; Palazzuoli A; Pontani A; Ghezzi A; Auteri A
Int J Cardiol; 2007 Jun; 119(1):41-7. PubMed ID: 17050011
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease.
Conard SE; Bays HE; Leiter LA; Bird SR; Rubino J; Lowe RS; Tomassini JE; Tershakovec AM
Am J Cardiol; 2008 Dec; 102(11):1489-94. PubMed ID: 19026302
[TBL] [Abstract][Full Text] [Related]
20. Randomised study to compare the efficacy and safety of isapgol plus atorvastatin versus atorvastatin alone in subjects with hypercholesterolaemia.
Jayaram S; Prasad HB; Sovani VB; Langade DG; Mane PR
J Indian Med Assoc; 2007 Mar; 105(3):142-5, 150. PubMed ID: 17824470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
